Screener
Pfizer PFE Biopharma — Investment Income, Dividend
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeDividend.
The source filing: Pfizer’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000078003-26-000054
(c)Biopharma’s earnings include dividend income from our investment in ViiV of $82 million in the first quarter of 2026 and $39 million in the first quarter of 2025 recorded in Other (income)/deductions––net. Biopharma’s earnings in the first quarter of 2025 also reflected a credit to Cost of Sales representing a favorable revision of our estimate of accrued royalties.
Item 1.
FAQ
- What is Pfizer's biopharma — investment income, dividend?
- Pfizer (PFE) reported biopharma — investment income, dividend of $82M in Q1 2026.
- How has Pfizer's biopharma — investment income, dividend changed year-over-year?
- Pfizer's biopharma — investment income, dividend increased by 110.3% year-over-year, from $39M to $82M.
- What is the long-term trend for Pfizer's biopharma — investment income, dividend?
- Over 4 years (2021 to 2025), Pfizer's biopharma — investment income, dividend has grown at a 12.4% compound annual growth rate (CAGR), from $166M to $265M.
- What does biopharma — investment income, dividend mean?
- Income derived from financial investments, such as dividends or interest, held by the biopharmaceutical segment. This represents non-operating income that contributes to the segment's overall financial health.
Ask your AI about Pfizer's biopharma — investment income, dividend.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude